PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Dimenhydrinate→

Dimenhydrinate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
523-87-5
Molecular formula
C24H28ClN5O3
Molecular weight
470 g/mol
Drug class
First-generation H1 antihistaminediphenhydramine–8-chlorotheophylline salt complex
Mechanism of action
The antihistamine component diphenhydramine antagonises central H1 receptors and has anticholinergic activity, reducing vestibular stimulation and emetic signalling. 8-Chlorotheophylline is included to reduce sedative effects in some formulations.
Indications / reported uses
  • Prevention and treatment of motion sickness
  • Symptomatic relief of nausea, vomiting and vertigo associated with vestibular disorders; route and age limits depend on the product label

Sources: US DailyMed — Dimenhydrinate products · NHS — Motion sickness medicines · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Dimenhydrinate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Dimenhydrinate Permitted Daily Exposure (PDE) report (the Dimenhydrinate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Dimenhydrinate Occupational Exposure Limit (OEL) report (the Dimenhydrinate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.